MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the second quarter ended June 30, 2025 and other recent business developments.
Related Questions
What is the status of the FDA/EMA regulatory pathway for their oncology candidates?
What were the key financial metrics (revenue, net loss, cash burn) for Q2 2025 and how do they compare to the same period last year?
Did Celcuity meet or exceed its internal guidance for Q2 2025 earnings and cash flow?
What are the details of any new partnership, licensing agreement, or acquisition announced?
What are the latest updates on the company's clinical trial milestones and timelines?
How does the current cash position and runway affect the company's runway to achieve commercialization or further fundraising?
What is the dilution impact from any recent or planned equity raises?
Are there any material changes in the management team or board that could affect execution?
What are the potential catalysts (clinical data releases, regulatory decisions) that could drive the stock in the short term?
What is the risk-reward profile for taking a position in CELC after this release?
How does the company's valuation and stock price react to this release relative to peers (e.g., other biotech firms with similar cash balances)?
How does the Q2 performance compare to analyst consensus estimates?